Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Indian J Exp Biol ; 42(8): 758-65, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15573523

ABSTRACT

L-Lysine HCI is being proposed to be a possible biocompatible adjuvant to enhance immune response by virtue of its probable non-specific bridging action and cellular proliferation properties. This proposal has been tried to be substantiated by designing an in vitro culture protocol, varying the concentration of L-lysine HCI and its further in vivo application. Splenic lymphocyte population has been extracted from mice and co-cultured with extracted mice macrophage population in presence of either Bacille Calmette Guerrin (BCG) or Hepatitis B surface antigen (HbsAg) and added L-lysine hydrochloride in culture media. Post incubation of these cultures, "taught" cell population has been adoptively transferred in naïve mice. These mice were then challenged by respective antigen dose, Change in Immune response with this challenge was noted. Antibody titre was followed in all the experiments as a measure of immune response. In adoptive immune transfer experiment of with HbsAg (AIT-HbsAg), similar to that with BCG (AIT-BCG), after the incubation period, antibody titre was higher in added lysine containing cultures in comparison with the control ones. Post transfer followed by antigen challenge, in AIT-BCG the expected augmentation in immune response was hardly visible. But in AIT-HbsAg, with the help of lysine booster, the animals responded better as far as the antibody titre is concerned.


Subject(s)
Lysine/administration & dosage , Tuberculosis Vaccines/administration & dosage , Animals , BCG Vaccine/administration & dosage , Female , Hepatitis B Vaccines/administration & dosage , Immunologic Factors/administration & dosage , Immunotherapy, Adoptive , In Vitro Techniques , Mice , Mice, Inbred BALB C
2.
Vaccine ; 21(32): 4722-7, 2003 Dec 01.
Article in English | MEDLINE | ID: mdl-14585682

ABSTRACT

L-Lysine HCl is being proposed to be a possible biocompatible adjuvant to enhance immune response by virtue of its probable non-specific bridging action and cellular proliferation properties. This proposal has been tried to be substantiated by carrying out experimentation where L-lysine HCl has been used as an adjuvant (various groups based on mode of application and frequency of booster dose were designed) in tuberculosis vaccination experiments with heat killed Mycobacterium tuberculosis (MTB) and Bacille Calmette Guerin (BCG). Antibody titre has been followed in all the experiments as a measure of immune response. Amongst the various groups designed, group 1A (L-lysine HCl was given at a separate site as that of the antigen; lysine booster was given to this group intermittently, i.e. lysine given on 0th, 7th, 14th, 21st days of immunization) came out as the stand-alone leader. This mode and frequency of application was then compared with a group which received a standard adjuvant, viz. alhydrogel. Results were obtained which showed the following order in terms of decreasing antibody titre: alhydrogel group > lysine group > control group. Considering the biocompatible nature of lysine in comparison with the reportedly hazardous nature of alum adjuvants, we propose L-lysine HCl as a probable adjuvant in vaccination.


Subject(s)
Adjuvants, Immunologic/pharmacology , BCG Vaccine/immunology , Lysine/pharmacology , Mycobacterium tuberculosis/immunology , Animals , Antibodies, Bacterial/blood , BCG Vaccine/administration & dosage , Cell Division/drug effects , Drug Synergism , Enzyme-Linked Immunosorbent Assay , Injections, Subcutaneous , Male , Mice
3.
Indian J Physiol Pharmacol ; 45(3): 367-72, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11881578

ABSTRACT

Monoclonal antibodies (MAb) constitute the centre of all in-vitro diagnostic measures and almost all in-vivo therapeutic manoeuvres now. Production emphasis for these antibodies is having a current shift from animal-based large-scale culture to in-vitro bioreactor-based high-density culture. One of the major difficulties in high-density culture is end-metabolite accumulation in batch and fed-batch cultures in the forms of H+, NH4+ etc.. thereby reducing cellular growth and secretions. In the present study, effects of added proton carries--NAD and NADP--over and above the metabolic pools of the molecules, were examined on the cellular growth and secretion kinetics. Although NADP fortification showed a remarkable improvement in cellular growth (time dependent 200-300% improvements compared to controls) and size, cumulative MAb titre was better with NAD fortification. Combined additional loads of the proton carriers would be interesting to study in high density culture conditions.


Subject(s)
Hybridomas/metabolism , Muromonab-CD3/biosynthesis , Protons , Algorithms , Animals , Cell Division/drug effects , Cell Line , Chromatography, High Pressure Liquid , Culture Media , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Hybridomas/drug effects , Lysine/pharmacology , Mice , NAD/pharmacology , Spectrophotometry, Ultraviolet , Stimulation, Chemical
SELECTION OF CITATIONS
SEARCH DETAIL
...